WO2011149206A3 - Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same - Google Patents
Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same Download PDFInfo
- Publication number
- WO2011149206A3 WO2011149206A3 PCT/KR2011/003514 KR2011003514W WO2011149206A3 WO 2011149206 A3 WO2011149206 A3 WO 2011149206A3 KR 2011003514 W KR2011003514 W KR 2011003514W WO 2011149206 A3 WO2011149206 A3 WO 2011149206A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- nebivolol hydrochloride
- composition containing
- preparing
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a pharmaceutical composition containing crystalline nebivolol hydrochloride and a method for preparing the same that enhances the dissolution rate of the crystalline nebivolol hydrochloride and minimizes the variance of dissolution rate to greatly enhance a desired therapeutic effect. The pharmaceutical composition includes: an active ingredient including an effective amount of crystalline nebivolol hydrochloride; and a pharmaceutically acceptable additive including starch, the pharmaceutical composition containing the crystalline nebivolol hydrochloride and the starch at a weight ratio of 1:15 to 1:40.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0050411 | 2010-05-28 | ||
KR1020100050411A KR20110130872A (en) | 2010-05-28 | 2010-05-28 | Pharmaceutical composition comprising crystalline nebivolol hydrochloride and method for manufacturing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011149206A2 WO2011149206A2 (en) | 2011-12-01 |
WO2011149206A3 true WO2011149206A3 (en) | 2012-04-19 |
Family
ID=45004516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/003514 WO2011149206A2 (en) | 2010-05-28 | 2011-05-12 | Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20110130872A (en) |
WO (1) | WO2011149206A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017119629A1 (en) * | 2016-01-08 | 2017-07-13 | 에리슨제약(주) | Pharmaceutical composition comprising nebivolol with improved dissolution rate |
KR102203229B1 (en) * | 2016-01-08 | 2021-01-14 | 에리슨제약(주) | Pharmaceutical composition with improved dissolution rate comprising nebivolol |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995022325A1 (en) * | 1994-02-17 | 1995-08-24 | Janssen Pharmaceutica N.V. | Compositions containing micronized nebivolol |
EP1741712A2 (en) * | 2004-07-30 | 2007-01-10 | Torrent Pharmaceuticals Ltd | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol |
KR20070044833A (en) * | 2004-06-04 | 2007-04-30 | 밀란 래보러토리즈, 인크. | Compositions comprising nebivolol |
EP1839658A1 (en) * | 2006-03-30 | 2007-10-03 | Hexal A/S | Pharmaceutical composition comprising micronized nebivolol |
-
2010
- 2010-05-28 KR KR1020100050411A patent/KR20110130872A/en not_active Application Discontinuation
-
2011
- 2011-05-12 WO PCT/KR2011/003514 patent/WO2011149206A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995022325A1 (en) * | 1994-02-17 | 1995-08-24 | Janssen Pharmaceutica N.V. | Compositions containing micronized nebivolol |
KR20070044833A (en) * | 2004-06-04 | 2007-04-30 | 밀란 래보러토리즈, 인크. | Compositions comprising nebivolol |
EP1741712A2 (en) * | 2004-07-30 | 2007-01-10 | Torrent Pharmaceuticals Ltd | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol |
EP1839658A1 (en) * | 2006-03-30 | 2007-10-03 | Hexal A/S | Pharmaceutical composition comprising micronized nebivolol |
Also Published As
Publication number | Publication date |
---|---|
WO2011149206A2 (en) | 2011-12-01 |
KR20110130872A (en) | 2011-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
MX2007007458A (en) | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof. | |
WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
WO2010122980A8 (en) | NOVEL THYROID HORMONE β RECEPTOR AGONIST | |
WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
UA105766C2 (en) | Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin | |
NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
EP2102225A4 (en) | Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient | |
WO2012087047A3 (en) | Percutaneous absorption preparation containing rivastigmine | |
WO2010087565A3 (en) | Novel use of piperine | |
WO2010097243A3 (en) | Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts | |
WO2009140341A3 (en) | Atorvastatin compositions | |
UA96622C2 (en) | Solid dosage forms comprising aliskiren obtained by solvent-free granulation process | |
EP2796450A4 (en) | 6-aminopyridine-3-ol derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same as active ingredients for preventing or treating diseases caused by angiogenesis | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
WO2010090494A3 (en) | Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof | |
MX2010007281A (en) | Pharmaceutical compositions of amlodipine and valsartan. | |
MD4563B1 (en) | Co-micronisation product comprising ulipristal acetate | |
EP2316420A8 (en) | Method to reduce pain | |
SA112330457B1 (en) | Phenyl-isoxazol derivatives and preparation process thereof | |
WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
WO2011132901A3 (en) | Novel benzamide derivatives | |
WO2014006636A3 (en) | Stable compositions of fesoterodine | |
WO2005120518A3 (en) | Use of atp analogues for treatment of cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11786839 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11786839 Country of ref document: EP Kind code of ref document: A2 |